Pharmacokinetic/Pharmacodynamic Evaluation of Deflazacort in Comparison to Methylprednisolone and Prednisolone

  title={Pharmacokinetic/Pharmacodynamic Evaluation of Deflazacort in Comparison to Methylprednisolone and Prednisolone},
  author={Helmut M{\"o}llmann and G{\"u}nther Hochhaus and Shashank Rohatagi and J{\"u}rgen Barth and Hartmut Derendorf},
  journal={Pharmaceutical Research},
AbstractPurpose. The pharmacokinetics and pharmacodynamics of deflazacort after oral administration (30 mg) to healthy volunteers were determined and compared with those of 20 mg of methylprednisolone and 25 mg of prednisolone. Methods. Methylprednisolone, prednisolone and the active metabolite of deflazacort, 21-desacetyldeflazacort, were measured in plasma using HPLC. For the assessment of pharmacodynamics, differential white blood cell counts were obtained over 24 hours. An integrated… 

Pharmacokinetics and Pharmacodynamics of Dexamethasone after Intravenous Administration in Camels: Effect of Dose

The pharmacokinetics and pharmacodynamics of dexamethasone were evaluated in healthy camels after single intravenous bolus doses of 0.05, 0.1 and 0.2 mg/kg body weight. Dexamethasone showed

Pharmacokinetics and Pharmacodynamics of Repository Corticotropin Injection Compared With Synthetic ACTH1‐24 Depot and Methylprednisolone in Healthy Subjects

The lower endogenous cortisol response of RCI was achieved despite higher observed mean plasma concentrations of N25‐deamidated porcine ACTH1‐39 (the pharmacokinetic marker for RCI) than of ACTH 1‐24.

A Review of Deflazacort for Patients With Duchenne Muscular Dystrophy

There is weak evidence to support improved functional outcomes, delayed onset of cardiomyopathy, reduction in scoliosis surgery, and improved survival with deflazacort, but these improvements are supported by relatively weak evidence.

A Pharmacokinetic/Pharmacodynamic Approach to Predict the Cumulative Cortisol Suppression of Inhaled Corticosteroids

The presented PK/PD approach allows valid predictions of CCS for single and short-term multiple dosing of inhaled corticosteroids and facilitates comparisons between different dosing regimens and steroids.

Head to head comparison of adverse effects and efficacy between high dose deflazacort and high dose prednisolone in systemic lupus erythematosus: a prospective cohort study

Comparable intake and tapering of high dose DFZ and PDN in active SLE revealed 2-fold less weight gain, 2- fold less hirsutism and 1.5-fold lower cushingoid severity index as well as lower glycaemic elevation in the DFZ group as compared to PDN group.

Metabolic considerations of drugs in the treatment of allergic diseases

The metabolism of antihistamine drugs, glucocorticoids, inhaled β-2 bronchodilators, anticholinergics and other drugs used in allergic diseases, such as cromoglycate, omalizumab, montelukast and epinephrine are analyzed.

Population Pharmacokinetics and Pharmacodynamics of Ciclesonide

The estimated EC50 is similar to mean Cmax from an 800–μg dose, further suggesting CIC‐AP has little effect on cortisol suppression, and the influence of select covariates on PK and/or pharmacodynamic parameters is assessed.



Pharmacokinetics and dose linearity testing of methylprednisolone phosphate.

The results indicate a rapid and predictable in vivo conversion of methylprednisolone phosphate to its active form methylpredisonsolone.

Evaluation of dose-related pharmacokinetics and pharmacodynamics of prednisolone in man

This study comprehensively elucidates the complexities of prednisolone pharmacokinetics and demonstrates how plasma concentration-time profiles of total or free prednisOLone can be utilized for evaluation of predisonsolone Pharmacodynamics.

Pharmacokinetics and pharmacodynamics of prednisolone after intravenous and oral administration.

The pharmacokinetics and pharmacodynamics of prednisolone were investigated according to four different routes of administration and the presence of pharmacodynamic corticosteroid effects on blood cell count and blood glucose was confirmed.

Pharmacodynamics of Methylprednisolone Phosphate After Single Intravenous Administration to Healthy Volunteers

An integrated pharmacokinetic/pharmacodynamic model was derived that translates the methylprednisolone plasma concentration–time profiles into effect– time profiles and allows prediction of pharmacodynamic effects for any single dose in the range studied at any time point.

Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults

The disposition rate of these two steroids is thus similar, in spite of their metabolic control by different enzymatic pathways and major influence of saturable transcortin binding on prednisolone elimination.

Receptor‐Based Pharmacokinetic‐Pharmacodynamic Analysis of Corticosteroids

The pharmacodynamics of three corticosteroids were investigated after intravenous administration of the phosphate esters of methylprednisolone, dexamethasone, and triamcinolone acetonide to healthy subjects as well as placebo, confirming the validity of the model.


No difference is found between total and free concentrations in the ability to predict inhibition of the mixed lymphocyte reaction over the range of drug concentrations observed, and no hyperbolic relationship is observed when the AUIC is plotted versus the AUC of free or total prednisolone, but not when AUic is plotting versus the oral dose.

Dose‐dependent prednisolone kinetics

Since it has been demonstrated that bioavailability, serum protein binding, prednisone‐prednisolone interconversion, and t½β remained constant over this dosage range, the altered Vd may account for the nonlinear relationship between AUC and dose.

Kinetics of methylprednisolone and its hemisuccinate ester

Saliva levels of methylprednisolone were low but paralleled plasma levels in the postdistribution phase, and dose dependency in the kinetics of both was indicated.

Kinetics and dynamics of prednisolone.

  • F. Frey
  • Medicine, Biology
    Endocrine reviews
  • 1987
Factors which modulate the kinetics and dynamics of prednisone/prednisolone, the most commonly prescribed synthetic glucocorticosteroids in clinical practice, are examined.